secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001070081-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

PTC Therapeutics announces preliminary 2024 revenue of $814M, exceeding guidance, and 2025 financial outlook
--------------------------------------------------------------------------------

- Preliminary 2024 total revenue ~$814M, net product revenue ~$601M, and Evrysdi royalties ~$211M.
- Four FDA approval applications submitted in 2024, including sepiapterin for PKU with FDA action date July 29, 2025 and CHMP opinion expected Q2 2025.
- License and collaboration agreement with Novartis for PTC518 (Huntington's disease) closed, with $1B upfront and up to $1.9B milestones.
- 2025 revenue guidance $600M-$800M; GAAP R&D and SG&A expense $805M-$835M; non-GAAP $730M-$760M.
- PIVOT-HD Phase 2 data readout expected Q2 2025; cash balance ~$1.1B plus additional $1B from Novartis upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000007/0001070081-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000007/tmb-20250113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer